All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

The effect of naldemedine on opioid-induced bowel dysfunction

Strong pain medicines, known as opioids, are very helpful for managing pain, but they often cause troublesome gut problems such as severe constipation, tummy ache, and bloating. This condition is called opioid-induced bowel dysfunction. This clinical trial looks at a medicine called Rizmoic (naldemedine). Researchers want to see how well it helps restore normal bowel function in adult men who are given tramadol, a common opioid painkiller. Participants will receive either Rizmoic or a dummy tablet (placebo). Scientists will track how quickly food and waste move through the digestive system. They will do this by using swallowable tracking capsules, MRI scans to measure fluid in the bowel, and simple symptom questionnaires. The goal is to understand how Rizmoic works inside the gut and whether it can provide reliable relief from opioid-related constipation.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Aalborg University Hospital
Enrolment target
20
Start
11 Dec 2023

What is this study about?

Opioid medicines, such as tramadol, morphine, and codeine, are widely used to treat moderate to severe pain. While they are very effective at reducing pain signals in the brain, they also attach to receptors in the gut. This slows down the natural squeezing movements of the intestines. As a result, waste stays in the bowel for too long, becoming hard and dry. For many people, this causes painful constipation, bloating, and nausea, which can severely impact daily life.

Rizmoic (also known by its scientific name, naldemedine) is a treatment designed specifically to tackle this problem. It blocks the unwanted effects of opioids in the digestive tract. Importantly, it does not enter the brain, meaning it should not stop the painkiller from doing its main job of relieving pain.

In this Phase II exploratory study, doctors want to look closely at the physical effects of Rizmoic. By using advanced imaging and small ingestible tracking devices, they will measure exactly how fast waste moves through each part of the digestive tract, how much water stays in the bowel, and how bowel pressure changes. This research will help doctors understand whether the treatment can effectively restart normal gut movement.

Key takeaways

  • The trial tests whether Rizmoic relieves constipation caused by opioid painkillers like tramadol.
  • Participation is open only to adult men aged 18 and older.
  • Researchers will use swallowable tracking capsules, MRI scans, and pressure tests to monitor gut speed.
  • Participants will receive either Rizmoic or an inactive dummy pill (placebo).
  • Taking part is voluntary, and you can withdraw from the study at any time.

Who may be eligible?

This study is currently open only to men aged 18 and older. Participants need to be in suitable health to take the study medicines, which include the painkiller tramadol and the study drug Rizmoic (or a matching placebo dummy pill).

Women are not eligible to take part in this particular trial. You may also be unable to join if you have certain existing bowel conditions, have had major stomach surgery, or have allergies to any of the study drugs.

Because the study uses MRI scans and small swallowed sensors, you will also need to be able to safely have an MRI scan. This means people with certain metal implants, pacemakers, or severe claustrophobia may not be able to participate. A study doctor will review your full medical history to make sure taking part is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am a man aged 18 or older.
  2. I am willing and able to take a daily painkiller (tramadol) during the study.
  3. I can safely undergo MRI scans (no incompatible metal implants or pacemakers).
  4. I am able to attend clinic visits and swallow small tracking capsules.
  5. I do not have a severe, unrelated gut condition that prevents me taking bowel treatments.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves several steps over a set study period. You will be asked to take tramadol (a slow-release painkiller) along with either Rizmoic or an identical dummy tablet (placebo). Neither you nor the study team will know which tablet you receive until the trial ends.

During the trial, you will visit the clinic for several specialized tests to see how your bowel is working. You will swallow small, safe tracking capsules that allow doctors to time how long it takes for things to pass through your stomach and intestines. You will also have MRI scans to look at bowel size and water content, and undergo a test measuring muscle pressure in the back passage. Throughout the study, you will fill in short daily questionnaires about your bowel habits, pain levels, and any withdrawal symptoms. The study team will monitor your health closely at every visit.

Potential risks and benefits

You may not get any direct personal health benefit from taking part, especially if you receive the placebo, but the findings could help improve treatments for people suffering from severe constipation in the future. As with any clinical trial, there are potential side effects. Tramadol can cause drowsiness, dizziness, or nausea, while Rizmoic can cause tummy cramps or diarrhoea. Some of the bowel tests, such as pressure measurements or MRI scans, may also cause brief physical discomfort. Your participation is completely voluntary. You can choose to stop and leave the study at any point without giving a reason, and your regular NHS medical care will not be affected in any way.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Denmark

Common questions

What is opioid-induced bowel dysfunction?

It is a common condition where opioid painkillers slow down the digestive system, leading to dry, hard stools, severe constipation, straining, and tummy discomfort.

Will taking Rizmoic stop my pain relief from working?

No. Rizmoic is designed to work mainly in the gut. It does not cross into the brain, so it should not interfere with how opioids relieve pain.

What is a placebo?

A placebo is a dummy pill that looks identical to the active medicine but contains no active drug. It helps researchers prove whether the real medicine is truly working.

Are the swallowable tracking capsules safe?

Yes. These are tiny, smooth electronic capsules designed to pass naturally and harmlessly through your digestive system while recording data.

Can I leave the study early if I change my mind?

Yes. Taking part is entirely your choice, and you are free to withdraw at any time without it affecting your standard medical care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "The effect of naldemedine on opioid-induced bowel dysfunctio…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.